KR930700525A - Antisense Inhibitors of Human Immunodeficiency Virus - Google Patents

Antisense Inhibitors of Human Immunodeficiency Virus

Info

Publication number
KR930700525A
KR930700525A KR1019920702823A KR920702823A KR930700525A KR 930700525 A KR930700525 A KR 930700525A KR 1019920702823 A KR1019920702823 A KR 1019920702823A KR 920702823 A KR920702823 A KR 920702823A KR 930700525 A KR930700525 A KR 930700525A
Authority
KR
South Korea
Prior art keywords
oligonucleotide
analog
hiv
animal
region
Prior art date
Application number
KR1019920702823A
Other languages
Korean (ko)
Other versions
KR0149680B1 (en
Inventor
제이. 엑커 데이비드
Original Assignee
크리스토퍼 케이. 미라벨리
아이시스 파마슈티칼스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/521,907 external-priority patent/US5166195A/en
Application filed by 크리스토퍼 케이. 미라벨리, 아이시스 파마슈티칼스, 인코포레이티드 filed Critical 크리스토퍼 케이. 미라벨리
Publication of KR930700525A publication Critical patent/KR930700525A/en
Application granted granted Critical
Publication of KR0149680B1 publication Critical patent/KR0149680B1/en

Links

Abstract

내용 없음.No content.

Description

인체 면역결핍 바이러스의 안티센스 억제제Antisense Inhibitors of Human Immunodeficiency Virus

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 선형의 HIV-1 tat mRNA서열을 묘사한 것이다.Figure 1 depicts a linear HIV-1 tat mRNA sequence.

제2도는 TAR/tat 전산 활성에 대한 세포 배양 분석에서 본 발명에 따른 일련의 올리고뉴클레오티드 및 그 유사체 활성을 나타낸다.2 shows a series of oligonucleotides and their analog activities according to the invention in cell culture assays for TAR / tat computational activity.

Claims (19)

하기 뉴클레오티드 서열의 어느 하나에 상응하는 최소한 6개의 인접 부단위로 구성된 올리고뉴클레오티드 또는 그 유사체.Oligonucleotides or analogs thereof consisting of at least six contiguous subunits corresponding to any of the following nucleotide sequences. 최소한 약 10개의 인접 부단위로 구성된 제 1항의 올리고뉴클레오티드 또는 그 유사체.The oligonucleotide of claim 1 consisting of at least about 10 contiguous subunits or an analog thereof. 제1항에 있어서, 상기 서열의 하나에 실질적으로 상응하는 올리고뉴클레오티드 또는 그 유사체.The oligonucleotide or analog thereof of claim 1 substantially corresponding to one of said sequences. HIV의 tat mRNA의 최소한 한 영역과 결합할 수 있는 올리고뉴클레오티드 또는 그 유사체.Oligonucleotides or analogs thereof capable of binding at least one region of the tat mRNA of HIV. 최소한 약 6개 내지 약 50개의 부단위로 구성되는 제 4항의 올리고뉴클레오티드 또는 그 유사체.The oligonucleotide of claim 4 or an analog thereof consisting of at least about 6 to about 50 subunits. 제4항에 있어서, 상기 영역과 헤테로 이중구조를 형성할 수 있는 올리고뉴클레오티드 또는 그 유사체.The oligonucleotide or analog thereof according to claim 4, which can form a hetero duplex with the region. 하기의 뉴클레오티드 서열의 어느 하나에 상응하는 최소한 6개의 인접 부단위로 구성되는 올리고뉴클레오티드 또는 그 유사체로 HIV tat 유전자 발현에 의한 질병을 갖는 동물을 접촉하는 것을 특징으로 하는 상기 동물의 치료 방법.A method of treating an animal characterized by contacting an animal having a disease caused by HIV tat gene expression with an oligonucleotide or an analog thereof consisting of at least six contiguous subunits corresponding to any one of the following nucleotide sequences. 제7항에 있어서, 상기 올리고뉴클레오티드 또는 그 유사체가 최소한 약 10개의 인접 부단위로 구성되는 경우의 치료방법.8. The method of claim 7, wherein the oligonucleotide or analog thereof consists of at least about 10 contiguous subunits. 제7항에 있어서, 상기 올리고뉴클레오티드 또는 그 유사체가 실질적으로 상기 서열의 하나에 상응하는 경우의 치료방법.8. The method of claim 7, wherein the oligonucleotide or analog thereof substantially corresponds to one of the sequences. HIV의 tat mRNA의 최소한 한 영역과 결합할 수 있는 올리고뉴클레오티드 또는 그 유사체로 HIV tat 유전자 발현에 의한 질병을 갖는 동물을 접촉하는 것을 특징으로 하는 상기 동물의 치료 방법.A method of treating an animal characterized by contacting an animal having a disease caused by HIV tat gene expression with an oligonucleotide or an analog thereof capable of binding at least one region of a tat mRNA of HIV. 제10항에 있어서, 상기 올리고뉴클레오티드 또는 그 유사체가 최소한 약 6개내지 약 50개의 부단위로 구성되는 경우의 치료방법.The method of claim 10, wherein the oligonucleotide or analog thereof consists of at least about 6 to about 50 subunits. 제10항에 있어서, 상기 올리고뉴클레오티드 또는 그 유사체가 상기 영역과 헤테로 이중구조를 형성할 수 있는 경우의 치료방법.The method of claim 10, wherein said oligonucleotide or analog thereof can form a hetero duplex with said region. HIV의 tat mRNA의 최소한 한 영역과 결합할 수 있는 올리고뉴클레오티드 또는 그 유사체로 HIV 에 감염된 동물을 접촉하는 것을 특징으로 하는 상기 동물의 치료방법.A method for treating an animal characterized by contacting an animal infected with HIV with an oligonucleotide or an analog thereof capable of binding at least one region of a tat mRNA of HIV. 하기의 뉴클레오티드 서열의 어느 하나에 상응하는 최소한 6개의 인접 부단위로 구성되는 올리고뉴클레오티드 또는 그 유사체로 HIV에 감염된 세포 또는 동물을 접촉하는 것을 특징으로 하는 HIV tat 유전자 발현을 조절하기 위한 방법.A method for regulating HIV tat gene expression, comprising contacting an HIV-infected cell or animal with an oligonucleotide or analog thereof consisting of at least six contiguous subunits corresponding to any of the following nucleotide sequences. HIV의 tat mRNA의 최소한 한 영역과 결합할 수 있는 올리고뉴클레오티드 또는 그 유사체로 HIV 에 감염된 동물을 접촉하는 것을 특징으로 하는 HIV tat 유전자 발현을 조절하기 위한 방법.A method for regulating HIV tat gene expression, comprising contacting an HIV infected animal with an oligonucleotide or analog thereof capable of binding at least one region of the tat mRNA of HIV. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019920702823A 1990-05-11 1991-04-22 Antisense inhibitors of the human immunodeficiency virus KR0149680B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US521,907 1990-05-11
US07/521,907 US5166195A (en) 1990-05-11 1990-05-11 Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
PCT/US1991/002734 WO1991018004A1 (en) 1990-05-11 1991-04-22 Antisense inhibitors of the human immunodeficiency virus

Publications (2)

Publication Number Publication Date
KR930700525A true KR930700525A (en) 1993-03-15
KR0149680B1 KR0149680B1 (en) 1998-08-17

Family

ID=24078638

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920702823A KR0149680B1 (en) 1990-05-11 1991-04-22 Antisense inhibitors of the human immunodeficiency virus

Country Status (13)

Country Link
US (2) US5166195A (en)
EP (1) EP0527916B1 (en)
JP (1) JPH0832242B2 (en)
KR (1) KR0149680B1 (en)
AT (1) ATE181960T1 (en)
AU (1) AU651593B2 (en)
BR (1) BR9106440A (en)
CA (1) CA2082631A1 (en)
DE (1) DE69131422T2 (en)
FI (1) FI925103A (en)
HU (1) HUT62912A (en)
NO (1) NO924258L (en)
WO (1) WO1991018004A1 (en)

Families Citing this family (155)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US5856088A (en) * 1989-07-11 1999-01-05 Gen-Probe Incorporated Detection of human immunodeficiency virus type 1
US6589734B1 (en) * 1989-07-11 2003-07-08 Gen-Probe Incorporated Detection of HIV
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5587361A (en) * 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5620963A (en) * 1991-10-15 1997-04-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5635488A (en) * 1991-10-15 1997-06-03 Isis Pharmaceuticals, Inc. Compounds having phosphorodithioate linkages of high chiral purity
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses
US6034233A (en) * 1990-05-04 2000-03-07 Isis Pharmaceuticals Inc. 2'-O-alkylated oligoribonucleotides and phosphorothioate analogs complementary to portions of the HIV genome
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
GB9016973D0 (en) * 1990-08-02 1990-09-19 Medical Res Council Viral growth inhibition
BR9106747A (en) * 1990-08-14 1993-07-20 Isis Pharmaceuticals Inc OLIGONUCLEOTIDEO OR OLIGONUCLEOTIDE ANALOG AND PROCESS FOR TREATING AN ANIMAL SUSPECTED TO BE INFECTED BY INFLUENZA VIRUS
US5786145A (en) * 1990-09-20 1998-07-28 Medical Research Council Oligonucleotide competitors for binding of HIV RRE to REV protein and assays for screening inhibitors of this binding
GB9020541D0 (en) * 1990-09-20 1990-10-31 Medical Res Council Viral growth inhibition
US6369209B1 (en) 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) * 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US5654284A (en) * 1991-10-15 1997-08-05 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating RAF kinase having phosphorothioate linkages of high chiral purity
US5599797A (en) * 1991-10-15 1997-02-04 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5607923A (en) * 1991-10-15 1997-03-04 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity
US5661134A (en) * 1991-10-15 1997-08-26 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
WO1993013114A1 (en) * 1991-12-24 1993-07-08 Isis Pharmaceuticals, Inc. COMPOSITIONS AND METHODS FOR MODULATING β-AMYLOID
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
AU4775193A (en) * 1992-07-17 1994-02-14 Aprogenex, Inc. In situ detection of nucleic acids using 3sr amplification
US5521061A (en) * 1992-07-17 1996-05-28 Aprogenex, Inc. Enhancement of probe signal in nucleic acid-mediated in-situ hybridization studies
WO1994002640A1 (en) * 1992-07-17 1994-02-03 Aprogenex, Inc. Multi reporter-labeled nucleic acid probes
CA2143678A1 (en) * 1992-09-10 1994-03-17 Kevin P. Anderson Compositions and methods for treatment of hepatitis c virus-associated diseases
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US20040049021A1 (en) * 1992-09-10 2004-03-11 Anderson Kevin P. Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US5985558A (en) * 1997-04-14 1999-11-16 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos
CA2110946A1 (en) * 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
CA2159103C (en) 1993-03-26 2002-03-12 Sherrol H. Mcdonough Detection of human immunodeficiency virus type 1
EP0705335A1 (en) * 1993-06-23 1996-04-10 Genesys Pharma Inc. Antisense oligonucleotides and therapeutic use thereof in human immunodeficiency virus infection
US5629413A (en) * 1993-07-19 1997-05-13 Gen-Probe Incorporated Oligonucleotides with activity against human immunodeficiency virus
US5739309A (en) * 1993-07-19 1998-04-14 Gen-Probe Incorporated Enhancement of oligonucleotide inhibition of protein production, cell proliferation and / or multiplication of infectious disease pathogens
AU679566B2 (en) 1993-09-03 1997-07-03 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US5807838A (en) * 1994-09-23 1998-09-15 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US5814619A (en) * 1994-04-08 1998-09-29 Isis Pharmacuticals, Inc. Oligonucleotide inhibition of P120
US5744362A (en) * 1994-05-31 1998-04-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6358932B1 (en) 1994-05-31 2002-03-19 Isis Pharmaceticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (en) * 1994-05-31 1999-07-15 파샬 비. 린네 Antisense oligonucleotide modulation of raf gene expression
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5733781A (en) * 1994-07-19 1998-03-31 Gen-Probe Incorporated Oligonucleotides and methods for inhibiting propagation of human immunodeficiency virus
US20030099959A1 (en) * 1995-04-12 2003-05-29 Kandimalla Ekambar R. Cooperative oligonucleotides
US6372427B1 (en) * 1995-04-12 2002-04-16 Hybridon, Inc. Cooperative oligonucleotides
US5985662A (en) * 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US5856099A (en) * 1996-05-21 1999-01-05 Isis Pharmaceuticals, Inc. Antisense compositions and methods for modulating type I interleukin-1 receptor expression
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6265388B1 (en) 1997-03-21 2001-07-24 President And Fellows Of Harvard College Antisense inhibition of angiogenin expression
CA2294988C (en) 1997-07-01 2015-11-24 Isis Pharmaceuticals Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
US5972639A (en) * 1997-07-24 1999-10-26 Irori Fluorescence-based assays for measuring cell proliferation
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US5877309A (en) 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
WO1999035279A1 (en) 1998-01-12 1999-07-15 Georgetown University Medical Center G protein-related kinase mutants in essential hypertension
JP2003524586A (en) * 1998-05-21 2003-08-19 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for parenteral administration of oligonucleotides
JP2002515514A (en) * 1998-05-21 2002-05-28 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for local delivery of oligonucleotides
EP1077722B1 (en) 1998-05-22 2006-08-09 Ottawa Health Research Institute Methods and products for inducing mucosal immunity
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6277967B1 (en) 1998-07-14 2001-08-21 Isis Pharmaceuticals, Inc. Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
ID30093A (en) * 1999-02-12 2001-11-01 Sankyo Co NEW ANALOGUE OF NUCLEOSIDE AND OLIGONUKLEOTIDE
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
JP4151751B2 (en) * 1999-07-22 2008-09-17 第一三共株式会社 New bicyclonucleoside analogues
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7105962B2 (en) * 2000-08-03 2006-09-12 Matsushita Electric Industrial Co., Ltd. Brushless motor for partable electronic equipment with wire treatment technique of coils
US20030096770A1 (en) * 2001-07-11 2003-05-22 Krotz Achim H. Enhancement of the stability of oligonucleotides comprising phosphorothioate linkages by addition of water-soluble antioxidants
EP1446162B1 (en) 2001-08-17 2008-10-15 Coley Pharmaceutical GmbH Combination motif immune stimulatory oligonucleotides with improved activity
AU2003202376B2 (en) * 2002-02-01 2008-10-30 Mcgill University Oligonucleotides comprising alternating segments and uses thereof
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7576066B2 (en) 2002-07-03 2009-08-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) 2002-07-03 2009-08-04 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
JP2006515277A (en) 2002-10-29 2006-05-25 コーリー ファーマシューティカル グループ， リミテッド Methods and products for treatment and prevention of hepatitis C virus infection
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
WO2004071453A2 (en) 2003-02-13 2004-08-26 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of pouchitis
JP2004283024A (en) * 2003-03-19 2004-10-14 Junsei Chemical Co Ltd New antisense oligonucleotide and anti-hiv agent
US7635560B2 (en) * 2003-04-17 2009-12-22 Genesis Group Inc. Pygopus in diagnosis and treatment of cancer
JP4879742B2 (en) * 2003-05-16 2012-02-22 ユニヴェルシテ ラヴァル Regulation of CNS chloride and use thereof
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
BRPI0416079A (en) 2003-10-30 2007-01-02 Coley Pharm Gmbh c-class oligonucleotide analogs with increased immunostimulatory potency
EA015670B9 (en) 2003-12-03 2012-01-30 Коуда Терапьютикс (Нз) Лтд. Antisense compounds targeted to connexins and methods of use thereof
JP2007537167A (en) * 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル Regulation of phospholipase C gamma and thereby regulation of pain and nociception
EP1766015A4 (en) * 2004-06-09 2008-10-01 Univ Mcgill Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US9248141B2 (en) 2005-02-03 2016-02-02 Coda Therapeutics, Inc. Methods of treatment by administering anti-connexin proteins and mimetics
AU2007281082A1 (en) * 2006-08-04 2008-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
ES2911034T3 (en) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Structure and use of 5' phosphate oligonucleotides
KR20100027091A (en) 2006-11-15 2010-03-10 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
DK2101791T3 (en) 2006-12-11 2015-01-05 Coda Therapeutics Inc ANTICONNEXIN POLYNUCLEOTIDES AS COMPOSITIONS AGAINST DEGRADED HEALTH
WO2009075881A2 (en) 2007-12-11 2009-06-18 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20100279921A1 (en) * 2007-12-11 2010-11-04 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
JP2011507861A (en) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド Use of anti-connexin polypeptide agents in combination with anti-connexin polynucleotide agents for the treatment of fibrotic conditions
CA2710380A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 poly nucleotide for the treatment of fibrotic conditions
WO2009085269A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
CA2710386A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Improved medical devices
WO2009085277A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
AU2008343754A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
AU2009255619A1 (en) * 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
US20120128673A1 (en) 2009-05-20 2012-05-24 Schering Corporation Modulation of pilr receptors to treat microbial infections
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
LT3505528T (en) 2011-04-21 2021-04-26 Glaxo Group Limited Modulation of hepatitis b virus (hbv) expression
WO2013148736A1 (en) 2012-03-27 2013-10-03 Coda Therapeutics, Inc. Compositions and treatments based on cadherin modulation
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2925500C (en) 2013-09-30 2023-03-14 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
EA201790434A1 (en) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед CHANNEL MODULATORS
CA2960054C (en) 2014-09-05 2023-11-14 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
CN107636159B (en) 2015-02-04 2022-06-14 百时美施贵宝公司 Method for selecting therapeutic molecules
EP3253875B1 (en) * 2015-02-04 2020-01-08 H. Hoffnabb-La Roche Ag Tau antisense oligomers and uses thereof
JP7495230B2 (en) 2017-04-28 2024-06-04 オークランド ユニサービシズ リミテッド Treatment methods and novel constructs
WO2019093649A1 (en) 2017-11-10 2019-05-16 주식회사 엘지화학 Novel compound and organic light-emitting element using same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959463A (en) * 1985-10-15 1990-09-25 Genentech, Inc. Intermediates
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
DE68929343T2 (en) * 1988-02-16 2002-09-12 Greatbatch Gen-Aid, Ltd. Modified cells with resistance to retroviral infections
WO1989008146A1 (en) * 1988-02-26 1989-09-08 Worcester Foundation For Experimental Biology Inhibition of htlv-iii by exogenous oligonucleotides
DE3907562A1 (en) * 1989-03-09 1990-09-13 Bayer Ag ANTISENSE OLIGONUCLEOTIDS FOR INHIBITING THE TRANSACTIVATOR TARGET SEQUENCE (TAR) AND THE SYNTHESIS OF THE TRANSACTIVATOR PROTEIN (TAT) FROM HIV-1 AND THE USE THEREOF
FR2648045B1 (en) * 1989-06-13 1991-09-27 Centre Nat Rech Scient ALPHA ANOMERIC OLIGONUCLEOTIDE COMPOUNDS INHIBITING REPLICATION OF RETROVIRUSES

Similar Documents

Publication Publication Date Title
KR930700525A (en) Antisense Inhibitors of Human Immunodeficiency Virus
NO924258L (en) ANTISENSE INHIBITORS FOR THE HUMAN IMMUNE WEIGHT VIRUS
KR930701465A (en) Oligonucleotides to mitigate the effects of cytomegalovirus infection
Wu et al. Molecular requirements for human immunodeficiency virus type 1 plus-strand transfer: analysis in reconstituted and endogenous reverse transcription systems
ES2063183T3 (en) ANTI-SENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF THE DAILY TRANSACTIVATOR SEQUENCE (TAR) AND THE SYNTHESIS OF THE HIV-I TRANSACTIVATOR PROTEIN (TAT) AND ITS USE.
DE69433626D1 (en) N-2 SUBSTITUTED PURINE
Bangham et al. Regulation of latency in the human T cell leukemia virus, HTLV-1
EP0549615A4 (en) Sugar modified oligonucleotides that detect and modulate gene expression
ES2061661T3 (en) VIRIC EXPRESSION INHIBITORS.
DE69833438D1 (en) HIV-SPECIFIC OLIGONUCLEOTIDES AND METHOD FOR THEIR USE
BR9007892A (en) OLIGONUCLEOTIDEO OR ANALOG OF OLIGONUCLEOTIDEO, PROCESSES FOR MODULATING THE EXPRESSION OF A PAPILLOMAVIRUS, FOR MODULATING THE EFFECTS OF AN INFECTION CAUSED BY PAPILLOMAVIRUS IN AN ANIMAL AND TO DETECT THE PRESENCE OR ABSENCE OF PAPILOMAVIRUS AND THE PRESENCE OF PAPILOMAVIRUS
Ghosh Glucocorticoid receptor-binding site in the human immunodeficiency virus long terminal repeat
KR930008138A (en) Attenuated Measles Vaccine Virus Strains Containing Specific Nucleotide Sequences and Their Complete Identification Methods
Rigl et al. Structural RNA Mimetics: N3 ‘→ P5 ‘Phosphoramidate DNA Analogs of HIV-1 RRE and TAR RNA Form A-Type Helices That Bind Specifically to Rev and Tat-Related Peptides
BR9106418A (en) PROCESS TO MODULATE THE EXPRESSION OF A GENE, OLIGONUCLOETIDE, OR OLIGONUCLEOTIDE ANALOG AND PROCESSES TO TREAT AN SUSPECTED ANIMAL HAVING HIV DISEASE AND INFECTION
Arzumanov et al. Inhibition of the HIV-1 Tat protein-TAR RNA interaction by 2'-O-methyl oligoribonucleotides
Raja et al. Kinetic analysis of the effect of HIV nucleocapsid protein (NCp) on internal strand transfer reactions
Kumar et al. SATB1-binding sequences and Alu-like motifs define a unique chromatin context in the vicinity of human immunodeficiency virus type 1 integration sites
Tsuchiya et al. Two distinct regions form a functional activation domain of the HTLV-1 trans-activator Tax1.
Xie et al. The first complete mitochondrial genome of a cyclophorid land snail, with implications for architaenioglossan relationships (Mollusca, Caenogastropoda, Cyclophoroidea)
Matsukuru Phosphorothioate Analogs of Oligodeoxynucleotide Inhibit Viral Replication of Human Immunodeficiency Virus (HIV): Inhibition of de Novo Infection in Uninfected Cells and Regulation of Viral Expression in Chronically Infected Cells
Sydow et al. The biological effects of coordination compounds of transitional metals. 6. Effect of 4-methyl-2-aminopyridine-palladium chloride and cis-dichlorodiammine-platinum (II) on retroviruses and the virus-associated RNA polymerase of the influenza virus
Greaves Ready and Abl